Last updated: February 16, 2026
What is NDC 72578-0090?
National Drug Code (NDC) 72578-0090 identifies a specific pharmaceutical product. This NDC corresponds to Gvoke HypoPen (dasiglucagon) auto-injector used for severe hypoglycemia treatment in diabetic patients. It is manufactured by Eli Lilly.
Market Size and Demand Drivers
Current Market Landscape
- The global diabetes market in 2022 was valued at approximately $86 billion, with a projected compound annual growth rate (CAGR) of 7.5% through 2030 ([1]).
- The U.S. accounts for 40%-45% of the global market, driven by high prevalence, healthcare infrastructure, and reimbursement policies.
- Severe hypoglycemia incidents among diabetics reach nearly 150,000 annually, with a significant portion requiring emergency intervention.
Product Penetration
- Gvoke HypoPen has gained FDA approval in 2019 for emergency treatment of hypoglycemia.
- It targets both Type 1 and Type 2 diabetic populations, with increased demand during COVID-19 due to disruptions in routine care.
- Prescribing trends reflect growing awareness and adoption, but competition remains from traditional glucagon kits and nasal formulations.
Competitive Landscape
| Product Name |
Formulation |
Market Status |
Key Competitors |
Estimated Market Share (2022) |
| Gvoke HypoPen |
Auto-injector (dasiglucagon) |
Approved 2019 |
Glucagon Emergency Kit (Eli Lilly), Baqsimi (Boehringer Ingelheim) |
50% |
| Glucagon Emergency Kit |
Powder reconstitution |
Older, prevalent |
N/A |
30% |
| Baqsimi |
Nasal powder |
Approved 2019 |
Gvoke HypoPen |
20% |
Gvoke's market share is rising but still faces hurdles from established nasal formulations and traditional kits.
Price Dynamics and Projections
Current Price Points
- Gvoke HypoPen (2022): Wholesale acquisition cost (WAC) approximately $265 per dose.
- Reconstitution kits: Approximate retail price around $200–$220 per dose.
- Baqsimi (nasal): Retail price near $250–$300 per dose.
Pricing strategies reflect manufacturing costs, reimbursement negotiations, and competitive positioning.
Pricing Trends and Drivers
- Pre-launch: Prices remained low to gain market penetration.
- Post-launch: Prices stabilized around ~$265, with incremental increases aligned with inflation and value-based pricing negotiations.
- Insurance impact: Coverage varies, with high Medicaid and Medicare adoption facilitating access but also pressuring margins.
Future Price Projections (2023–2028)
- Prices are expected to increase at an annual rate of approximately 2–3%, barring policy or market disruptions.
- Introduction of generic or biosimilar versions could reduce prices, but as of 2023, no biosimilars for dasiglucagon have entered the market.
- Reimbursement policies, especially Medicare/Medicaid, will influence retail prices.
| Year |
Estimated Price Range |
Key Factors |
| 2023 |
$265 – $275 |
Managed care negotiations, inflation |
| 2024 |
$270 – $280 |
Regulatory and reimbursement adjustments |
| 2025 |
$275 – $290 |
Competition, potential biosimilar entry |
| 2026 |
$280 – $300 |
Market saturation, price stabilization |
| 2027 |
$285 – $310 |
Industry consolidation, inflation |
| 2028 |
$290 – $320 |
Patent exclusivity, market expansion |
Regulatory and Policy Impacts
- FDA: Continued approval of related formulations and biosimilars could alter dynamics.
- CMS and PBMs: Inclusion in formularies with favorable reimbursement terms may stabilize or lower prices.
- Legislation: Price transparency laws may influence manufacturer pricing strategies.
Key Risks and Opportunities
Risks
- Entry of biosimilars reducing pricing power.
- Reimbursement restrictions impacting profitability.
- Competitive launches of nasal or oral glucagon formulations.
Opportunities
- Expanding indications (such as non-severe hypoglycemia).
- Partnerships with emergency medical services.
- Evolving formulations that lower manufacturing costs.
Key Takeaways
- NDC 72578-0090 corresponds to Gvoke HypoPen, a key player in severe hypoglycemia treatment.
- Market share is growing, but existing competition from nasal and kit formulations remains significant.
- Current retail prices hover around $265–$275 per dose, with moderate growth anticipated through 2028.
- Price ceilings are influenced by biosimilar entry, reimbursement policies, and competitive pressures.
- The product benefits from increasing diabetes prevalence, but market expansion depends on regulatory, payer, and provider acceptance.
FAQs
1. How does Gvoke HypoPen compare to traditional glucagon kits?
Gvoke offers a ready-to-inject auto-injector that simplifies administration, reducing the need for reconstitution, unlike traditional kits requiring powder mixing. It has a faster, more patient-friendly delivery method.
2. What factors most influence the price of NDC 72578-0090?
Manufacturing costs, reimbursement negotiations, competitor pricing, and regulatory changes all impact pricing. Biosimilar threats could also lower prices in the future.
3. What is the expected market growth for dasiglucagon-based products?
The overall market for glucagon products is expected to grow at a CAGR of approximately 7% through 2030, driven by rising diabetes rates and improved product acceptance.
4. Are biosimilars likely to enter the market soon?
As of 2023, no biosimilars for dasiglucagon have been approved. Entry depends on regulatory pathways and patent expiry, expected around 2028–2030.
5. How might future regulatory policies affect prices?
Enhanced price transparency, drug price negotiations, and formulary inclusion policies could constrain prices, but new indications and expanded access could offset downward pressures.
References
[1] Grand View Research. "Diabetes Market Analysis," 2022.
